Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

RayzeBio, Inc. - Common Stock (NQ: RYZB )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about RayzeBio, Inc. - Common Stock

Bristol Myers Squibb Announces Expiration of RayzeBio Tender Offer
From Bristol Myers Squibb
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Masonite International Corporation (NYSE – DOOR), ZeroFox Holdings, Inc. (Nasdaq – ZFOX), RayzeBio, Inc. (Nasdaq – RYZB)
From Brodsky & Smith LLC
Via GlobeNewswire
Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period
From Bristol Myers Squibb
Via Business Wire
Pancreatic Cancer Treatments Poised for Major Advances in 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:INCY),(NASDAQ:TNGX),(NASDAQ:RYZB),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
IPO watch 2024: Which new stocks will hit the market?
Expectations are high for the 2024 IPO market, with Reddit, Databricks, and Shein debuts anticipated, hinting at a substantial influx of new public companies. 
Via MarketBeat
Topics Initial Public Offering
Exposures Securities Market
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq – RYZB), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Daseke, Inc. (Nasdaq – DSKE), Karuna Therapeutics, Inc. (Nasdaq – KRTX)
From Brodsky & Smith LLC
Via GlobeNewswire
RAYZEBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RayzeBio, Inc. - RYZB
From Kahn Swick & Foti, LLC
Via Business Wire
Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
Bristol Myers announced two acquisitions in a week. The pharma giant is boosting its neuroscience pipeline with Karuna and its oncology pipeline with RayzeBio. 
Via MarketBeat
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq – RYZB), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Daseke, Inc. (Nasdaq – DSKE), Karuna Therapeutics, Inc. (Nasdaq – KRTX)
From Brodsky & Smith LLC
Via GlobeNewswire
RYZB Stock Alert: Halper Sadeh LLC Is Investigating RayzeBio, Inc.
From Halper Sadeh LLC
Via Business Wire
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
From Rayzebio, Inc.
Via GlobeNewswire
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
From Bristol Myers Squibb
Via Business Wire
RayzeBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Rayzebio, Inc.
Via GlobeNewswire
RayzeBio to Participate in Upcoming Investor Conferences in November 2023
From Rayzebio, Inc.
Via GlobeNewswire
RayzeBio Appoints Industry Leader Tim Van Hauwermeiren to Its Board of Directors
From Rayzebio, Inc.
Via GlobeNewswire
FDA selects RayzeBio to Participate in the Inaugural CDRP Program to Expedite Commercial Manufacturing Readiness for RYZ101 in GEP-NETs
From Rayzebio, Inc.
Via GlobeNewswire
RayzeBio to Present at European Society for Medical Oncology (ESMO) Congress
From Rayzebio, Inc.
Via GlobeNewswire
RayzeBio, Inc. Announces Closing of Upsized $358 Million Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From RayzeBio, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.